ADAM-Afatinib Diarrhea Assessment and Management
Public ClinicalTrials.gov record NCT01814553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Study identification
- NCT ID
- NCT01814553
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- afatinib Drug
- loperamide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2013
- Primary completion
- Jun 30, 2015
- Completion
- Jun 30, 2015
- Last update posted
- Oct 30, 2016
2013 – 2015
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1200.167.01009 Boehringer Ingelheim Investigational Site | Santa Rosa | California | — | — |
| 1200.167.01020 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1200.167.01018 Boehringer Ingelheim Investigational Site | Port Saint Lucie | Florida | — | — |
| 1200.167.01012 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 1200.167.01007 Boehringer Ingelheim Investigational Site | Skokie | Illinois | — | — |
| 1200.167.01008 Boehringer Ingelheim Investigational Site | Skokie | Illinois | — | — |
| 1200.167.01001 Boehringer Ingelheim Investigational Site | Morristown | New Jersey | — | — |
| 1200.167.01014 Boehringer Ingelheim Investigational Site | Corvallis | Oregon | — | — |
| 1200.167.01002 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | — | — |
| 1200.167.01006 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | — | — |
| 1200.167.01005 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 1200.167.01003 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01814553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01814553 live on ClinicalTrials.gov.